Most Read Articles
31 May 2016
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

01 Mar 2018
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.

E6201 shows potential in treatment of advanced solid malignancies

12 Jun 2018

A phase I study of E6201 has shown the feasibility and safety of an intermittent regimen of 320 mg/m2 by intravenous (IV) infusion once-weekly (qw) for the first 3 weeks of a 28-day cycle in patients with advanced solid malignancies, including melanoma.

“Additionally, we show preliminary evidence of clinical efficacy, confirming the potential of MEK (mitogen-activated protein kinase/extracellular signal-regulated kinase) inhibition and selective MEK1 inhibition, as a therapeutic strategy in cancer,” the investigators said.

In part A of the study (dose escalation), sequential cohorts received E6201 IV over 30 min qw (days [D]1 + 8 + 15 of a 28-day cycle), starting at 20 mg/m2, increasing to 720 mg/m2 or the maximum tolerated dose (MTD). In part B (expansion), patients with B-type Raf (BRAF)-mutated or wild-type (WT) melanoma received E6201 320 mg/m2 IV over 60 minutes qw (D1 + 8 + 15 of a 28-day cycle) or 160 mg/m2 IV twice-weekly (D1 + 8 + 15 + 18 of a 28-day cycle; BRAF-mutated only).

MTD was 320 mg/m2 qw in part A (n=25) and confirmed in part B (n=30). QT prolongation (n=4) and eye disorders (n=3) were some of the reported adverse events.

There was a dose-related exposure of E6201, with pharmacokinetics characterized by extensive distribution and fast elimination. Partial response was reported in one patient during part A (BRAF-mutated papillary thyroid cancer; 480 mg/m2 qw) and in three during part B (2 BRAF-mutated melanoma; 1 BRAF-WT melanoma; all receiving 320 mg/m2 qw).

“E6201 is being further investigated in a phase I/II trial in patients with advanced haematologic malignancies with the FLT3 mutation,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
31 May 2016
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

01 Mar 2018
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.